San Diego, CA--June 8, 2011--Mentor Capital, Inc. (OTCMarket:MNTR) announced that five new cancer companies have requested that Mentor Capital draft and forward funding contracts with a value of $40 Million for their review and potential execution. Additionally, twenty other cancer fighting companies have initiated investment funding information requests that could lead to contracts and funding to capture the remainder of Mentor Capital’s current $125 Million funding limit.

Mentor met with managements and screened approximately forty, often leading- edge, cancer companies for potential investment at the June 3-7, 2011 ASCO cancer conference in Chicago, IL. Mentor is experiencing that the typical requested cancer funding increment is $10 Million and is to be applied to support a round of FDA drug development trials.

Mentor Capital, which only is acquiring and investing in cancer related companies, initiated its current round of funding May 5, 2011. If the drafted contracts are concluded, Mentor will hold $20 per share in cancer assets. The company currently has $2.50 per Mentor share in cancer assets from twelve companies. The majority of funding for participating cancer companies will come from the exercise of Mentor Capital warrants at a $7.00 per share strike price. The Mentor Capital structure and typical cancer investments can be tracked through investor information and summaries of the several smaller stock purchases made for the Cancer Immunotherapy Index presented at www.MentorCapital.com.

Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.


__________

Chet Billingsley is the CEO and Chairman of Mentor Capital, Inc. Mentor Capital, Inc. invests in leading-edge cancer companies across all companies in its proprietary Cancer Immunotherapy Index and seeks to overweight acquisition or stock purchase funding in those companies with the greatest promise.

Chet Billingsley, CEO

Mentor Capital, Inc.
P.O. Box 1709
Ramona, CA 92065
(760) 788-4700
(760) 788-2525 Fax

 ↑ Back to Top